Ozempic, Wegovy Reduced Risk of These 10 Cancers
Ozempic, Wegovy Reduced Risk of These 10 Cancers
New Research Uncovers Potential Cancer-Fighting Properties of Semaglutide Medications
A recent study published in the Journal of the American Medical Association (JAMA) has found evidence that the use of semaglutide medications, such as Ozempic and Wegovy, may help reduce the likelihood of developing cancers related to obesity in individuals diagnosed with type 2 diabetes.
What are Semaglutide Medications?
Semaglutide is a type of medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications are used to treat type 2 diabetes by stimulating the release of insulin and reducing blood sugar levels. Ozempic and Wegovy are two popular semaglutide medications that have been shown to be effective in reducing the risk of cardiovascular events in patients with type 2 diabetes.
What Did the Study Find?
The study analyzed data from over 1.6 million patients with type 2 diabetes who were treated with either semaglutide, insulin, or metformin. The researchers found that patients who took semaglutide had a significantly reduced risk of developing 10 different types of cancer, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic, and multiple myeloma cancers.
Which Cancers Were Affected?
The study found that patients who took semaglutide had a reduced risk of developing the following cancers:
- 65% reduced risk of gallbladder cancer
- 63% reduced risk of meningioma
- 59% reduced risk of pancreatic cancer
- 53% reduced risk of liver cancer (hepatocellular carcinoma)
- 48% reduced risk of ovarian cancer
- 46% reduced risk of colorectal cancer
- 41% reduced risk of multiple myeloma
- 40% reduced risk of esophageal cancer
- 26% reduced risk of endometrial cancer
- 24% reduced risk of kidney cancer
What Does This Mean?
The findings of this study suggest that semaglutide medications may have potential cancer-fighting properties. This is significant because obesity is a known risk factor for many types of cancer, and the development of effective treatments for obesity-related cancers is a major public health concern.
What Do the Experts Say?
Yoni Resnick, PharmD, director of pharmacy clinical services with New England Cancer Specialists, believes that the findings of this study are exciting and potentially groundbreaking. “It’s exciting to see that there might be some smoke as it relates to these medications, potentially reducing the risk of some cancers that have historically been statistically related to obesity,” he said.
Jennie Stanford, MD, an obesity medicine physician for InteliHealth, agrees that the study’s findings are significant. “I think we’re at the tip of the iceberg when it comes to understanding the benefits of the GLP-1 receptor agonists,” she said. “As we learn more and more about what they’re able to do, I think we’ll be able to see possibilities for using them in dementia, in obesity-associated cancers and other medical problems that are linked back to the same underlying mechanism.”
Conclusion
The study’s findings suggest that semaglutide medications may have potential cancer-fighting properties and may be a valuable tool in the prevention and treatment of obesity-related cancers. While more research is needed to confirm these findings, the potential implications are significant and could have a major impact on public health.
FAQs
Q: What is semaglutide?
A: Semaglutide is a type of medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It is used to treat type 2 diabetes by stimulating the release of insulin and reducing blood sugar levels.
Q: What did the study find?
A: The study found that patients who took semaglutide had a significantly reduced risk of developing 10 different types of cancer, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic, and multiple myeloma cancers.
Q: Which cancers were affected?
A: The study found that patients who took semaglutide had a reduced risk of developing the following cancers:
- Gallbladder cancer
- Meningioma
- Pancreatic cancer
- Liver cancer (hepatocellular carcinoma)
- Ovarian cancer
- Colorectal cancer
- Multiple myeloma
- Esophageal cancer
- Endometrial cancer
- Kidney cancer
Q: What do the experts say?
A: Yoni Resnick, PharmD, and Jennie Stanford, MD, both believe that the findings of this study are significant and potentially groundbreaking. They believe that the study’s findings could have major implications for the prevention and treatment of obesity-related cancers.
Q: What are the next steps?
A: The study’s authors recommend that further research is needed to confirm these findings and to explore the potential mechanisms by which semaglutide may reduce the risk of cancer.
